The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for Lynparza (olaparib) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.
The PARP inhibitor Lynparza (olaparib) significantly improved progression-free survival (PFS) as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase 3 SOLO-1 trial presented at the 2018 ESMO Congress.
Treatment options for patients with HER2-positive breast cancer continue to expand, especially after the Food and Drug Administration (FDA) approval of Nerlynx (neratinib) earlier in 2017 and the more recent priority review designation of Perjeta (pertuzumab).
The way that newly diagnosed patients with multiple myeloma is treated has changed significantly over recent years, especially as new drugs moved into the treatment realm for the disease, says Shaji K. Kumar, M.D.
In an interview with CURE, Ruben Mesa, M.D., director, UT Health San Antonio Cancer Center, shed light on these recent updates in PV and ET, and discussed the proper therapeutic management of these diseases.
In a recent study, researchers were working on identifying different molecular targets to better provide personalized care to patients with ovarian cancer. To do this, they examined more than 4,000 tumor specimins.
We’re moving into a new era of understanding with genetic abnormalities in colorectal cancer (CRC) as researchers continue to investigate tumor sidedness and the role of microsatellite instability (MSI) testing.
There is currently no uniform procedure for patients with double-hit lymphoma (DHL) that prolongs benefit. Some patients receive autologous stem-cell transplantation to reduce the risk of relapse, but the jury is still out on the impact that it has.